An open-label, single-dose desipramine, multiple-dose HCV-796, sequential 3-period study to determine the pharmacokinetics of the potential drug interaction between HCV-796 and desipramine

Trial Profile

An open-label, single-dose desipramine, multiple-dose HCV-796, sequential 3-period study to determine the pharmacokinetics of the potential drug interaction between HCV-796 and desipramine

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2008

At a glance

  • Drugs Nesbuvir (Primary) ; Desipramine
  • Indications Hepatitis C; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 16 Apr 2008 Development of nesbuvir has been discontinued due to safety issues, according to a ViroPharma media release.
    • 11 Apr 2008 According to NCT report study status changed to completed.
    • 24 Jan 2008 The expected completion date for this trial is now 1 Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top